Samsung Biologics built the world's biggest drug plants before the orders came

Samsung Biologics was founded in 2011 and broke ground on Plant 1 — 30,000 liters — within a month. The industry then considered about 90,000 liters the practical efficiency limit for a single biologics plant; Plant 2 jumped to 154,000 liters, and each later plant set a new world record: 180,000, 240,000 and 180,000 liters.

The bet was that scale would win contracts: with 784,000 liters of capacity the company holds an overwhelming global lead in biopharmaceutical contract development and manufacturing, and it has secured manufacturing approvals from FDA and EMA plus 17 of the world's top-20 pharma as customers.

Management calls it a three-pillar strategy — capacity expansion, portfolio diversification into mRNA, ADC and cell-gene therapies, and geographic expansion. Since its 2016 listing, revenue has grown at over 40% a year, from 294.6 billion won to roughly 15 times that, with cumulative orders above 17.6 billion dollars.

The model was not obvious: for years clients hesitated to outsource biologics, and building ahead of demand carried heavy capital risk. Samsung treated the mega-plant itself as the product that changed the CMO paradigm, standardizing processes so clients could scale without transferring their own technology.